Transcriptomic response and immunological responses to chimpanzee adenovirus- and MVA viral-vectored vaccines for RSV in healthy adults.
RSV
antibodies
human trials
transcriptomics
vaccine
viral vectors
Journal
Clinical and experimental immunology
ISSN: 1365-2249
Titre abrégé: Clin Exp Immunol
Pays: England
ID NLM: 0057202
Informations de publication
Date de publication:
24 03 2023
24 03 2023
Historique:
received:
03
05
2022
revised:
30
10
2022
accepted:
06
01
2023
medline:
28
3
2023
pubmed:
10
1
2023
entrez:
9
1
2023
Statut:
ppublish
Résumé
Cohorts of healthy younger adults (18-50yrs) and healthy older adults (60-75yrs) were immunized intramuscularly or intranasally with an adenovirus-vectored RSV vaccine (PanAd3-RSV) as a prime dose and boosted with PanAd3-RSV or a poxvirus-vectored vaccine (MVA-RSV) encoding the same insert. Whole blood gene expression was measured at baseline, 3- and 7-days post vaccination. Intramuscular prime vaccination with PanAd3-RSV induced differential expression of 643 genes (DEGs, FDR < 0.05). Intranasal prime vaccination with PanAd3-RSV did not induce any differentially expressed genes (DEGs) in blood samples at 3 days post vaccination. Intranasally primed participants showed greater numbers of DEGS on boosting than intramuscularly primed participants. The most highly enriched biological processes related to DEGs after both prime and boost vaccination were type-1 interferon related pathways, lymphocytic and humoral immune responses.
Identifiants
pubmed: 36622786
pii: 6979728
doi: 10.1093/cei/uxad003
pmc: PMC10038321
doi:
Substances chimiques
Antibodies, Viral
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
269-279Subventions
Organisme : Wellcome Trust
Pays : United Kingdom
Informations de copyright
© The Author(s) 2023. Published by Oxford University Press on behalf of the British Society for Immunology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Références
PLoS One. 2014 Jul 09;9(7):e101591
pubmed: 25007091
Genome Med. 2015 Nov 10;7:114
pubmed: 26555212
Mol Ther. 2011 Dec;19(12):2269-76
pubmed: 21862998
Expert Rev Vaccines. 2013 Apr;12(4):379-93
pubmed: 23560919
Mol Ther Methods Clin Dev. 2015 May 20;2:15018
pubmed: 26015988
Curr Opin Immunol. 2016 Aug;41:47-54
pubmed: 27286566
BMC Infect Dis. 2006 Dec 13;6:175
pubmed: 17166282
Lancet. 2015 Aug 29;386(9996):857-66
pubmed: 26248676
Sci Transl Med. 2014 Nov 5;6(261):261ra153
pubmed: 25378645
Sci Transl Med. 2013 Oct 2;5(205):205ra134
pubmed: 24089406
Stat Appl Genet Mol Biol. 2004;3:Article3
pubmed: 16646809
Mol Ther. 2014 Mar;22(3):668-674
pubmed: 24374965
J Infect. 2019 May;78(5):382-392
pubmed: 30742894
Lancet. 2020 Aug 15;396(10249):467-478
pubmed: 32702298
JAMA. 2016 Apr 19;315(15):1610-23
pubmed: 27092831
Bioinformatics. 2005 May 1;21(9):2067-75
pubmed: 15657102
J Infect Dis. 2014 Jul 15;210(2):224-33
pubmed: 24495909
J Virol. 2012 May;86(10):5422-36
pubmed: 22398282
Vaccine. 2002 Jan 31;20(9-10):1340-53
pubmed: 11818152
Bioinformatics. 2003 Feb 12;19(3):368-75
pubmed: 12584122
J Exp Med. 2006 Feb 20;203(2):413-24
pubmed: 16461338
Nat Commun. 2013;4:2836
pubmed: 24284865
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50
pubmed: 16199517
Lancet. 2020 Jun 13;395(10240):1845-1854
pubmed: 32450106
J Virol. 2007 Jan;81(1):215-28
pubmed: 17050593
PLoS One. 2013;8(3):e55435
pubmed: 23536756
Sci Transl Med. 2015 Aug 12;7(300):300ra127
pubmed: 26268314
BMJ Open. 2015 Oct 28;5(10):e008748
pubmed: 26510727
N Engl J Med. 2016 Apr 28;374(17):1635-46
pubmed: 25629663
Nat Med. 2004 Nov;10(11):1240-4
pubmed: 15502839
J Immunol. 2016 Aug 15;197(4):1242-51
pubmed: 27412417